MA38397A1 - Agglomérats inhalables de particules de support poreuses et médicament micronisé - Google Patents
Agglomérats inhalables de particules de support poreuses et médicament microniséInfo
- Publication number
- MA38397A1 MA38397A1 MA38397A MA38397A MA38397A1 MA 38397 A1 MA38397 A1 MA 38397A1 MA 38397 A MA38397 A MA 38397A MA 38397 A MA38397 A MA 38397A MA 38397 A1 MA38397 A1 MA 38397A1
- Authority
- MA
- Morocco
- Prior art keywords
- inhalable
- agglomerates
- porous carrier
- carrier particles
- particles
- Prior art date
Links
- 239000002245 particle Substances 0.000 title abstract 6
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000004480 active ingredient Substances 0.000 abstract 4
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
- 238000001694 spray drying Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361784842P | 2013-03-14 | 2013-03-14 | |
| PCT/IB2014/059739 WO2014141135A1 (en) | 2013-03-14 | 2014-03-13 | Respirable agglomerates of porous carrier particles and micronized drug |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA38397A1 true MA38397A1 (fr) | 2018-01-31 |
Family
ID=50478894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA38397A MA38397A1 (fr) | 2013-03-14 | 2014-03-13 | Agglomérats inhalables de particules de support poreuses et médicament micronisé |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US9452139B2 (enExample) |
| EP (1) | EP2968570A1 (enExample) |
| JP (1) | JP6374414B2 (enExample) |
| KR (1) | KR20150129716A (enExample) |
| CN (1) | CN105188757B (enExample) |
| AU (2) | AU2014229265A1 (enExample) |
| BR (1) | BR112015021814A2 (enExample) |
| CA (1) | CA2905615A1 (enExample) |
| CL (1) | CL2015002632A1 (enExample) |
| EA (1) | EA201591729A1 (enExample) |
| GT (1) | GT201500295A (enExample) |
| HK (1) | HK1212616A1 (enExample) |
| IL (1) | IL240963A (enExample) |
| MA (1) | MA38397A1 (enExample) |
| MX (1) | MX2015012814A (enExample) |
| PE (1) | PE20151655A1 (enExample) |
| PH (1) | PH12015501882A1 (enExample) |
| SA (1) | SA515361055B1 (enExample) |
| SG (1) | SG11201506397QA (enExample) |
| TN (1) | TN2015000395A1 (enExample) |
| WO (1) | WO2014141135A1 (enExample) |
| ZA (1) | ZA201505768B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110064811A1 (en) | 2005-12-28 | 2011-03-17 | Patricia Hurter | Solid forms of N-[2,4-BIS(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| TWI433674B (zh) | 2006-12-28 | 2014-04-11 | Infinity Discovery Inc | 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類 |
| US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
| WO2011133751A2 (en) | 2010-04-22 | 2011-10-27 | Vertex Pharmaceuticals Incorporated | Process of producing cycloalkylcarboxamido-indole compounds |
| CA2898682A1 (en) * | 2013-01-31 | 2014-08-07 | Prosonix Limited | Pharmaceutical compositions comprising multi-component crystalline particles suitable for use in inhalation therapy |
| US9452139B2 (en) * | 2013-03-14 | 2016-09-27 | Novartis Ag | Respirable agglomerates of porous carrier particles and micronized drug |
| JP2017508776A (ja) * | 2014-03-27 | 2017-03-30 | ノバルティス アーゲー | 医薬品有効成分吸入用の噴霧乾燥した水中油中固体分散体 |
| SI3424534T1 (sl) | 2014-04-15 | 2021-08-31 | Vertex Pharmaceutical Incorporated | Farmacevtski sestavki za zdravljenje bolezni, ki jih povzroča regulator transmembranske prevodnosti pri cistični fibrozi |
| AU2015330923B2 (en) | 2014-10-07 | 2020-03-12 | Vertex Pharmaceuticals Incorporated | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |
| WO2016142708A2 (en) * | 2015-03-10 | 2016-09-15 | Cipla Limited | Pharmaceutical composition |
| US10423736B2 (en) * | 2015-08-28 | 2019-09-24 | University Of British Columbia | Methods and systems for simulating hydrodynamics in gas-solid fluidized beds |
| EP3335699A1 (en) * | 2016-12-15 | 2018-06-20 | H e x a l Aktiengesellschaft | Selexipag formulation in liquisolid system |
| CN106943350A (zh) * | 2017-03-14 | 2017-07-14 | 上海现代药物制剂工程研究中心有限公司 | 含毒蕈碱受体拮抗剂和β2受体激动剂的气雾剂及制备方法 |
| WO2019060595A1 (en) * | 2017-09-20 | 2019-03-28 | Teva Branded Pharmaceutical Products R&D, Inc. | INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM |
| US20200324064A1 (en) * | 2019-04-10 | 2020-10-15 | Cai Gu Huang | Inhalation Device for Administering Powdered Pharmaceutical Composition |
| US20200375945A1 (en) * | 2019-06-03 | 2020-12-03 | Cai Gu Huang | Inhalable formulation of a solution containing indacaterol maleate and glycopyrronium bromide |
| CN112137957B (zh) * | 2019-06-26 | 2022-07-29 | 长风药业股份有限公司 | 一种药用吸入气雾剂及其制备方法 |
| EP4013245A1 (en) * | 2019-08-15 | 2022-06-22 | Abbott Laboratories | Nutritional powder manufacturing process using micronization, and powder composition |
| KR20220167315A (ko) * | 2020-04-13 | 2022-12-20 | 유니버지퇴트슈피탈 바젤 | Lsd 용량 확인 |
| CN114344285B (zh) * | 2020-10-14 | 2023-11-14 | 江苏恒瑞医药股份有限公司 | 改良的可吸入团聚物 |
| CN116546980A (zh) * | 2020-12-11 | 2023-08-04 | 江苏恒瑞医药股份有限公司 | 用于肺部递送的药物组合物 |
| CN113318097A (zh) * | 2021-04-29 | 2021-08-31 | 珠海瑞思普利医药科技有限公司 | 一种抗特发性肺纤维化的粉雾剂及制备方法 |
| CN116785239A (zh) * | 2022-03-17 | 2023-09-22 | 上海惠永药物研究有限公司 | 喷雾冷冻干燥制备微球的方法 |
| CN116785246A (zh) * | 2022-03-17 | 2023-09-22 | 上海惠永药物研究有限公司 | 一种药物微球及含其的气雾剂 |
| CN117357485B (zh) * | 2023-11-01 | 2024-09-24 | 山东京卫制药有限公司 | 一种改良的可吸入的载体颗粒及应用 |
| WO2025256638A1 (zh) * | 2024-06-14 | 2025-12-18 | 上海济昀生物科技有限公司 | 一种混悬型三联吸入气雾剂组合物及其制备方法 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2956062A (en) | 1959-02-26 | 1960-10-11 | Robins Co Inc A H | Esters of amino alcohols |
| IT1016489B (it) | 1974-03-18 | 1977-05-30 | Isf Spa | Inalatore |
| ATE8790T1 (de) | 1981-02-02 | 1984-08-15 | Schering Corporation | Aromatische heterocyclische steroidester, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten. |
| SE448277B (sv) | 1985-04-12 | 1987-02-09 | Draco Ab | Indikeringsanordning vid en doseringsanordning for lekemedel |
| US6536427B2 (en) | 1990-03-02 | 2003-03-25 | Glaxo Group Limited | Inhalation device |
| AR245596A1 (es) | 1991-06-26 | 1994-02-28 | Schering Corp | Dispositivo inhalador de medicamentos en polvo |
| KR0163472B1 (ko) | 1992-12-18 | 1998-11-16 | 에릭 에스. 딕커 | 분말 약품용 흡입기 |
| US6794357B1 (en) * | 1993-06-24 | 2004-09-21 | Astrazeneca Ab | Compositions for inhalation |
| US5837699A (en) | 1994-01-27 | 1998-11-17 | Schering Corporation | Use of mometasone furoate for treating upper airway passage diseases |
| RU2146153C1 (ru) | 1994-09-21 | 2000-03-10 | Инхейл Терапьютик Системз | Устройство и способ распыления лекарственных средств в виде сухого порошка (варианты) |
| DE69618624T2 (de) | 1996-01-03 | 2002-08-08 | Glaxo Group Ltd., Greenford | Inhaliervorrichtung |
| NZ331361A (en) | 1996-02-21 | 2000-01-28 | Schering Corp | Powder inhaler including swirl means for changing the flow direction of the powder and chimney means for reversing the flow direction |
| ES2195121T3 (es) | 1996-11-11 | 2003-12-01 | Christian R Noe | Uso de una sal farmaceuticamente aceptable de (3r,2'r)-3-((ciclopentilhidroxifenilacetil)oxi)-1,1-dimetilpirrolidinio para la preparacion de un medicamento. |
| US6613795B2 (en) | 1996-11-11 | 2003-09-02 | Christian Noe | Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments |
| US6010935A (en) | 1997-08-21 | 2000-01-04 | Micron Technology, Inc. | Self aligned contacts |
| US6565885B1 (en) | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
| UA73924C2 (en) | 1998-10-09 | 2005-10-17 | Nektar Therapeutics | Device for delivering active agent formulation to lungs of human patient |
| PL200941B1 (pl) | 1998-11-13 | 2009-02-27 | Jagotec Ag | Suchy proszkowy preparat inhalacyjny |
| US20070212422A1 (en) | 1999-11-10 | 2007-09-13 | Manfred Keller | Dry powder for inhalation |
| GB9913083D0 (en) | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
| ATE331544T1 (de) | 1999-05-28 | 2006-07-15 | Nektar Therapeutics | Gerät und verfahren zur aerosolisierung einer pharmazeutischen pulverzusammensetzung |
| US20010029947A1 (en) | 1999-12-17 | 2001-10-18 | Steve Paboojian | Receptacles to facilitate the extraction of powders |
| US7069929B2 (en) | 2000-02-01 | 2006-07-04 | Quadrant Technologies Limited | Dry powder inhaler |
| US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
| TWI290473B (en) | 2000-05-10 | 2007-12-01 | Alliance Pharma | Phospholipid-based powders for drug delivery |
| GB0201677D0 (en) | 2002-01-25 | 2002-03-13 | Glaxo Group Ltd | Medicament dispenser |
| CA2509216A1 (en) | 2002-12-13 | 2004-07-01 | Adagit | Pharmaceutical porous particles |
| ES2383367T5 (es) | 2003-04-09 | 2021-03-31 | Novartis Ag | Aparato de pulverización en forma de aerosol con protección de entrada de aire |
| GB0317374D0 (en) | 2003-07-24 | 2003-08-27 | Glaxo Group Ltd | Medicament dispenser |
| GB2407042B (en) | 2003-10-17 | 2007-10-24 | Vectura Ltd | Inhaler |
| ES2767934T3 (es) | 2004-02-24 | 2020-06-19 | Microdose Therapeutx Inc | Aparato de administración de medicamentos a base de chorro sintético |
| GB0410712D0 (en) | 2004-05-13 | 2004-06-16 | Novartis Ag | Organic compounds |
| GB0413960D0 (en) | 2004-06-22 | 2004-07-28 | Novartis Ag | Organic compounds |
| ITMI20051999A1 (it) | 2005-10-21 | 2007-04-22 | Eratech S R L | Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita' |
| GB0613161D0 (en) * | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
| CA2654801C (en) | 2006-06-30 | 2014-08-19 | Novartis Ag | Quinolinone derivatives and their pharmaceutical compositions |
| CA2667225C (en) | 2006-10-25 | 2015-06-09 | Novartis Ag | Powder dispersion apparatus, method of making and using the apparatus, and components that can be used on the apparatus and other devices |
| BRPI0913021A2 (pt) | 2008-05-15 | 2015-10-13 | Novartis Ag | distribuição pulmonar de uma fluoroquinolona |
| MX344153B (es) | 2009-04-09 | 2016-12-07 | Novartis Ag | Proceso para la preparación de sales de pirrolidinio. |
| US8815258B2 (en) * | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
| KR101730684B1 (ko) | 2010-04-01 | 2017-04-26 | 키에시 파르마슈티시 엣스. 피. 에이. | 흡입용 건조 분말을 위한 담체 입자 제조 방법 |
| JOP20120023B1 (ar) * | 2011-02-04 | 2022-03-14 | Novartis Ag | صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية |
| US9452139B2 (en) * | 2013-03-14 | 2016-09-27 | Novartis Ag | Respirable agglomerates of porous carrier particles and micronized drug |
-
2014
- 2014-03-10 US US14/202,262 patent/US9452139B2/en active Active
- 2014-03-13 AU AU2014229265A patent/AU2014229265A1/en not_active Abandoned
- 2014-03-13 MX MX2015012814A patent/MX2015012814A/es unknown
- 2014-03-13 EA EA201591729A patent/EA201591729A1/ru unknown
- 2014-03-13 MA MA38397A patent/MA38397A1/fr unknown
- 2014-03-13 WO PCT/IB2014/059739 patent/WO2014141135A1/en not_active Ceased
- 2014-03-13 PE PE2015001910A patent/PE20151655A1/es not_active Application Discontinuation
- 2014-03-13 HK HK16100598.8A patent/HK1212616A1/zh unknown
- 2014-03-13 CN CN201480015125.XA patent/CN105188757B/zh active Active
- 2014-03-13 KR KR1020157024586A patent/KR20150129716A/ko not_active Ceased
- 2014-03-13 JP JP2015562509A patent/JP6374414B2/ja active Active
- 2014-03-13 BR BR112015021814A patent/BR112015021814A2/pt active Search and Examination
- 2014-03-13 CA CA2905615A patent/CA2905615A1/en not_active Abandoned
- 2014-03-13 EP EP14716933.8A patent/EP2968570A1/en not_active Withdrawn
- 2014-03-13 SG SG11201506397QA patent/SG11201506397QA/en unknown
-
2015
- 2015-08-11 ZA ZA2015/05768A patent/ZA201505768B/en unknown
- 2015-08-26 PH PH12015501882A patent/PH12015501882A1/en unknown
- 2015-08-31 IL IL240963A patent/IL240963A/en active IP Right Grant
- 2015-09-04 TN TN2015000395A patent/TN2015000395A1/en unknown
- 2015-09-11 CL CL2015002632A patent/CL2015002632A1/es unknown
- 2015-09-13 SA SA515361055A patent/SA515361055B1/ar unknown
- 2015-09-14 GT GT201500295A patent/GT201500295A/es unknown
-
2016
- 2016-08-17 US US15/238,842 patent/US9744178B2/en active Active
-
2017
- 2017-05-16 AU AU2017203258A patent/AU2017203258B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| SA515361055B1 (ar) | 2016-11-13 |
| CL2015002632A1 (es) | 2016-03-28 |
| IL240963A0 (en) | 2015-11-30 |
| CN105188757A (zh) | 2015-12-23 |
| GT201500295A (es) | 2017-09-28 |
| US20160354388A1 (en) | 2016-12-08 |
| KR20150129716A (ko) | 2015-11-20 |
| AU2014229265A1 (en) | 2015-09-03 |
| SG11201506397QA (en) | 2015-09-29 |
| JP6374414B2 (ja) | 2018-08-15 |
| TN2015000395A1 (en) | 2017-01-03 |
| BR112015021814A2 (pt) | 2017-07-18 |
| US9744178B2 (en) | 2017-08-29 |
| AU2017203258A1 (en) | 2017-06-08 |
| AU2017203258B2 (en) | 2019-06-20 |
| EA201591729A1 (ru) | 2016-05-31 |
| US9452139B2 (en) | 2016-09-27 |
| EP2968570A1 (en) | 2016-01-20 |
| PE20151655A1 (es) | 2015-11-26 |
| WO2014141135A1 (en) | 2014-09-18 |
| IL240963A (en) | 2017-05-29 |
| PH12015501882A1 (en) | 2015-12-07 |
| MX2015012814A (es) | 2016-02-03 |
| CA2905615A1 (en) | 2014-09-18 |
| JP2016512494A (ja) | 2016-04-28 |
| HK1212616A1 (zh) | 2016-06-17 |
| ZA201505768B (en) | 2017-03-29 |
| US20140302147A1 (en) | 2014-10-09 |
| CN105188757B (zh) | 2019-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA38397A1 (fr) | Agglomérats inhalables de particules de support poreuses et médicament micronisé | |
| MA34449B1 (fr) | Formulation de poudre seche comprenant un inhibiteur de phosphodiesterase | |
| PH12021550166A1 (en) | Nlrp3 inflammasome inhibitors | |
| DE60129573D1 (de) | Verfahren zur sprühtrocknung von zusammensetzungen enthaltend fenofibrat | |
| UA107499C2 (uk) | Склад сухого порошку, який містить антимускариновий засіб | |
| BRPI0411165A (pt) | composição farmacêutica, forma de unidade de dosagem e métodos para preparar seu uso | |
| ATE487720T1 (de) | 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer | |
| ATE470443T1 (de) | Indol-1-yl-essigsäurederivate | |
| BRPI0508170A (pt) | formulações farmacêuticas para inaladores de pó seco, que compreendem um ingrediente ativo de potência de baixa dosagem | |
| BR112015020443A2 (pt) | desamorfização de formulações secadas por atomização via mistura por atomização | |
| EA201700182A1 (ru) | Состав для повышения стабильности лекарственного препарата, содержащий по меньшей мере один сухой порошок, полученный распылительной сушкой | |
| RU2016132762A (ru) | Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением | |
| MA43876B1 (fr) | Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale | |
| EA201401309A1 (ru) | Фармацевтическая композиция для ингаляции, содержащая аклидиний, и её применение | |
| EA200500387A1 (ru) | Композиции для ингаляции с высоким содержанием лекарственных веществ | |
| EA202092922A1 (ru) | Фармацевтический состав с улучшенной растворимостью и биологической доступностью | |
| EA201170583A1 (ru) | Новая композиция для лечения эссенциальной тромбоцитемии | |
| EA026665B1 (ru) | Твердые формы препаратов иматиниба, ресуспензируемые непосредственно перед применением | |
| EA200801614A1 (ru) | Фармацевтическая композиция, содержащая монтелукаст | |
| EA201792159A1 (ru) | Способ получения сухих порошкообразных смесей | |
| EA202091127A1 (ru) | Фармацевтические композиции, включающие сафинамид | |
| MA35698B1 (fr) | Nouvelle composition du 3,4-diaminopyridin pour le traitement de la fatigabilité musculaire associée à des troubles neurovégétatifs. | |
| EA201171014A1 (ru) | Средство противовирусной и иммуностимулирующей активности, способ получения средства противовирусной и иммуностимулирующей активности, способ профилактики и лечения инфекционных болезней | |
| EA200101157A1 (ru) | 14β-H-СТЕРОЛЫ, СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И ПРИМЕНЕНИЕ ЭТИХ ПРОИЗВОДНЫХ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ, РЕГУЛИРУЮЩИХ МЕЙОЗ | |
| EP3686185A4 (en) | FLORINE-DERIVATIVE OR PHARMACEUTICAL SALT THEREOF, MANUFACTURING METHOD FOR ITS AND PHARMACEUTICAL COMPOSITION THEREOF, AS AN ACTIVE SUBSTANCE FOR THE PREVENTION OR TREATMENT OF HCV-ASSOCIATED DISEASES |